The August issue of Life Science Compliance Update provides an interesting look at the recently released 2014 Open Payments data. One article outlines the drastic decline in research payments from 2013. Another looks into what manufacturers are writing in Open Payments comment spaces—free-text boxes that allow manufacturers to offer context to their various transfers of value.
Also in this month’s edition, Paul Silver, the Managing Director and Practice Leader at Huron Life Sciences, as well as other members of his team at Huron, contributed an article entitled “Open Payments Driving Adjustments in HCP Engagement Practices.” The article provides insight into how organizations may use Open Payments for compliance and commercial insights. The article includes specific examples from the Open Payments database, and offers best practices for how to analyze the information.
The issue also features an article on the Open Payments “Review and Dispute” process by Abraham Gitterman, JD, an FDA/Healthcare Associate at the law firm Arnold and Porter. In it, Gitterman offers recommendations for manufacturers to consider when addressing physician disputes, not only to resolve inaccuracies to ensure compliance with the Sunshine Act, but also to identify and potentially mitigate additional compliance risks that may arise from or be attributed to disputes.
This publication also includes an article titled “Ensuring Compliant MSL Interactions with Healthcare Providers.” As manufacturers continue to move away from a traditional sales rep model, the government has adjusted its spotlight onto how Medical Science Liaisons (MSLs) interact with healthcare providers. This article provides a look at risk areas and government guidance for compliance within the MSL role.
To view the table of contents for this issue, click here.